APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell and Gene Therapy (CGT) Logistic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cell and Gene Therapy (CGT) Logistic Market Outlook and Growth Opportunities 2026

3 May 2026196 pages

Choose your research edition.

Industry ResearchCell and Gene Therapy (CGT) Logistic Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell and Gene Therapy (CGT) Logistic Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Cell and Gene Therapy (CGT) Logistic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell and Gene Therapy (CGT) Logistic Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell and Gene Therapy (CGT) Logistic Market Analysis and Forecast 2026-2032213 pages · $4,950 USD

Market perspective

The global Cell and Gene Therapy (CGT) Logistic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cell and Gene Therapy (CGT) Logistic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cell and Gene Therapy (CGT) Logistic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell and Gene Therapy (CGT) Logistic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cell and Gene Therapy (CGT) Logistic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cell and Gene Therapy (CGT) Logistic market include Cencora, Inc（World Courier）, QuickStat, Associated Couriers, LLC, Central Pharma, POLAR EXPRES, Biocair, time:matters, Mercury Business Services and Cardinal Health, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cell and Gene Therapy (CGT) Logistic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cell and Gene Therapy (CGT) Logistic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cell and Gene Therapy (CGT) Logistic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell and Gene Therapy (CGT) Logistic market.

Cell and Gene Therapy (CGT) Logistic Segment by Company

Cencora, Inc（World Courier）

QuickStat

Associated Couriers, LLC

Central Pharma

POLAR EXPRES

Biocair

time:matters

Mercury Business Services

Cardinal Health

CRYOPDP

Cryoport

NMDP BioTherapies

McKesson

Excel Courier

Almac

BEAM Logistics

Cell and Gene Therapy (CGT) Logistic Segment by Type

National Transportation

International Transportation

Cell and Gene Therapy (CGT) Logistic Segment by Application

Biotech and Pharmaceutical Companies

Hospitals

Research Organizations

Other

Cell and Gene Therapy (CGT) Logistic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cell and Gene Therapy (CGT) Logistic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cell and Gene Therapy (CGT) Logistic key companies, revenue, market share, and recent developments.

3. To split the Cell and Gene Therapy (CGT) Logistic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cell and Gene Therapy (CGT) Logistic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cell and Gene Therapy (CGT) Logistic significant trends, drivers, influence factors in global and regions.

6. To analyze Cell and Gene Therapy (CGT) Logistic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy (CGT) Logistic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy (CGT) Logistic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy (CGT) Logistic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell and Gene Therapy (CGT) Logistic industry.

Chapter 3: Detailed analysis of Cell and Gene Therapy (CGT) Logistic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cell and Gene Therapy (CGT) Logistic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cell and Gene Therapy (CGT) Logistic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cell and Gene Therapy (CGT) Logistic Industry Trends Table 2. Cell and Gene Therapy (CGT) Logistic Industry Drivers Table 3. Cell and Gene Therapy (CGT) Logistic Industry Opportunities and Challenges Table 4. Cell and Gene Therapy (CGT) Logistic Industry Restraints Table 5. Global Cell and Gene Therapy (CGT) Logistic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cell and Gene Therapy (CGT) Logistic Revenue Share by Company (2021-2026) Table 7. Global Cell and Gene Therapy (CGT) Logistic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cell and Gene Therapy (CGT) Logistic Key Company Manufacturing Base & Headquarters Table 9. Global Cell and Gene Therapy (CGT) Logistic Company, Product Type & Application Table 10. Global Cell and Gene Therapy (CGT) Logistic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cell and Gene Therapy (CGT) Logistic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of National Transportation Table 15. Significant Companies of International Transportation Table 16. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type (2021-2026) Table 20. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Biotech and Pharmaceutical Companies Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Research Organizations Table 24. Significant Companies of Other Table 25. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application (2021-2026) Table 29. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application (2027-2032) Table 30. Global Cell and Gene Therapy (CGT) Logistic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Region (2021-2026) Table 33. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Region (2027-2032) Table 35. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Cell and Gene Therapy (CGT) Logistic Sales Value Market Share by Country (2021-2026) Table 38. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Cell and Gene Therapy (CGT) Logistic Sales Value Market Share by Country (2027-2032) Table 40. Cencora, Inc（World Courier） Company Information Table 41. Cencora, Inc（World Courier） Business Overview Table 42. Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 44. Cencora, Inc（World Courier） Recent Development Table 45. QuickStat Company Information Table 46. QuickStat Business Overview Table 47. QuickStat Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. QuickStat Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 49. QuickStat Recent Development Table 50. Associated Couriers, LLC Company Information Table 51. Associated Couriers, LLC Business Overview Table 52. Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 54. Associated Couriers, LLC Recent Development Table 55. Central Pharma Company Information Table 56. Central Pharma Business Overview Table 57. Central Pharma Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Central Pharma Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 59. Central Pharma Recent Development Table 60. POLAR EXPRES Company Information Table 61. POLAR EXPRES Business Overview Table 62. POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 64. POLAR EXPRES Recent Development Table 65. Biocair Company Information Table 66. Biocair Business Overview Table 67. Biocair Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Biocair Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 69. Biocair Recent Development Table 70. time:matters Company Information Table 71. time:matters Business Overview Table 72. time:matters Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. time:matters Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 74. time:matters Recent Development Table 75. Mercury Business Services Company Information Table 76. Mercury Business Services Business Overview Table 77. Mercury Business Services Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Mercury Business Services Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 79. Mercury Business Services Recent Development Table 80. Cardinal Health Company Information Table 81. Cardinal Health Business Overview Table 82. Cardinal Health Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Cardinal Health Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 84. Cardinal Health Recent Development Table 85. CRYOPDP Company Information Table 86. CRYOPDP Business Overview Table 87. CRYOPDP Cell and Gene Therapy (CGT) Logistic Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. CRYOPDP Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 89. CRYOPDP Recent Development Table 90. Cryoport Company Information Table 91. Cryoport Business Overview Table 92. Cryoport Cell and Gene Therapy (CGT) Logistic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Cryoport Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 94. Cryoport Recent Development Table 95. NMDP BioTherapies Company Information Table 96. NMDP BioTherapies Business Overview Table 97. NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 99. NMDP BioTherapies Recent Development Table 100. McKesson Company Information Table 101. McKesson Business Overview Table 102. McKesson Cell and Gene Therapy (CGT) Logistic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. McKesson Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 104. McKesson Recent Development Table 105. Excel Courier Company Information Table 106. Excel Courier Business Overview Table 107. Excel Courier Cell and Gene Therapy (CGT) Logistic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Excel Courier Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 109. Excel Courier Recent Development Table 110. Almac Company Information Table 111. Almac Business Overview Table 112. Almac Cell and Gene Therapy (CGT) Logistic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Almac Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 114. Almac Recent Development Table 115. BEAM Logistics Company Information Table 116. BEAM Logistics Business Overview Table 117. BEAM Logistics Cell and Gene Therapy (CGT) Logistic Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. BEAM Logistics Cell and Gene Therapy (CGT) Logistic Product Portfolio Table 119. BEAM Logistics Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Cell and Gene Therapy (CGT) Logistic Product Image Figure 2. Global Cell and Gene Therapy (CGT) Logistic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032) & (US$ Million) Figure 4. Global Cell and Gene Therapy (CGT) Logistic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. National Transportation Image Figure 8. International Transportation Image Figure 9. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type (2021-2032) Figure 12. Biotech and Pharmaceutical Companies Image Figure 13. Hospitals Image Figure 14. Research Organizations Image Figure 15. Other Image Figure 16. Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application (2021-2032) Figure 19. Global Cell and Gene Therapy (CGT) Logistic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032) & (US$ Million) Figure 22. North America Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032) & (US$ Million) Figure 28. South America Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • National Transportation
  • International Transportation
Applications
  • Biotech and Pharmaceutical Companies
  • Hospitals
  • Research Organizations
  • Other
Companies covered
  • Cencora, Inc（World Courier）
  • QuickStat
  • Associated Couriers, LLC
  • Central Pharma
  • POLAR EXPRES
  • Biocair
  • time:matters
  • Mercury Business Services
  • Cardinal Health
  • CRYOPDP
  • Cryoport
  • NMDP BioTherapies
  • McKesson
  • Excel Courier
  • Almac
  • BEAM Logistics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cell and Gene Therapy (CGT) Logistic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cell and Gene Therapy (CGT) Logistic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cell and Gene Therapy (CGT) Logistic Market Dynamics
  1. 2.1 Cell and Gene Therapy (CGT) Logistic Industry Trends
  2. 2.2 Cell and Gene Therapy (CGT) Logistic Industry Drivers
  3. 2.3 Cell and Gene Therapy (CGT) Logistic Industry Opportunities and Challenges
  4. 2.4 Cell and Gene Therapy (CGT) Logistic Industry Restraints
3 Cell and Gene Therapy (CGT) Logistic Market by Company
  1. 3.1 Global Cell and Gene Therapy (CGT) Logistic Company Revenue Ranking in 2025
  2. 3.2 Global Cell and Gene Therapy (CGT) Logistic Revenue by Company (2021-2026)
  3. 3.3 Global Cell and Gene Therapy (CGT) Logistic Company Ranking (2024-2026)
  4. 3.4 Global Cell and Gene Therapy (CGT) Logistic Company Manufacturing Base and Headquarters
  5. 3.5 Global Cell and Gene Therapy (CGT) Logistic Company Product Type and Application
  6. 3.6 Global Cell and Gene Therapy (CGT) Logistic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cell and Gene Therapy (CGT) Logistic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cell and Gene Therapy (CGT) Logistic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cell and Gene Therapy (CGT) Logistic Market by Type
  1. 4.1 Cell and Gene Therapy (CGT) Logistic Type Introduction
  2. 4.1.1 National Transportation
  3. 4.1.2 International Transportation
  4. 4.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type
  5. 4.2.1 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type (2021-2032)
5 Cell and Gene Therapy (CGT) Logistic Market by Application
  1. 5.1 Cell and Gene Therapy (CGT) Logistic Application Introduction
  2. 5.1.1 Biotech and Pharmaceutical Companies
  3. 5.1.2 Hospitals
  4. 5.1.3 Research Organizations
  5. 5.1.4 Other
  6. 5.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application
  7. 5.2.1 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Application (2021-2032)
  9. 5.2.3 Global Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application (2021-2032)
6 Cell and Gene Therapy (CGT) Logistic Regional Value Analysis
  1. 6.1 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032)
  7. 6.3.2 North America Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032)
  10. 6.4.2 Europe Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032)
  16. 6.6.2 South America Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cell and Gene Therapy (CGT) Logistic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cell and Gene Therapy (CGT) Logistic Sales Value Share by Country, 2025 VS 2032
7 Cell and Gene Therapy (CGT) Logistic Country-level Value Analysis
  1. 7.1 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cell and Gene Therapy (CGT) Logistic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cell and Gene Therapy (CGT) Logistic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cell and Gene Therapy (CGT) Logistic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cell and Gene Therapy (CGT) Logistic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cencora, Inc（World Courier）
  2. 8.1.1 Cencora, Inc（World Courier） Company Information
  3. 8.1.2 Cencora, Inc（World Courier） Business Overview
  4. 8.1.3 Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cencora, Inc（World Courier） Cell and Gene Therapy (CGT) Logistic Product Portfolio
  6. 8.1.5 Cencora, Inc（World Courier） Recent Developments
  7. 8.2 QuickStat
  8. 8.2.1 QuickStat Company Information
  9. 8.2.2 QuickStat Business Overview
  10. 8.2.3 QuickStat Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 QuickStat Cell and Gene Therapy (CGT) Logistic Product Portfolio
  12. 8.2.5 QuickStat Recent Developments
  13. 8.3 Associated Couriers, LLC
  14. 8.3.1 Associated Couriers, LLC Company Information
  15. 8.3.2 Associated Couriers, LLC Business Overview
  16. 8.3.3 Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Associated Couriers, LLC Cell and Gene Therapy (CGT) Logistic Product Portfolio
  18. 8.3.5 Associated Couriers, LLC Recent Developments
  19. 8.4 Central Pharma
  20. 8.4.1 Central Pharma Company Information
  21. 8.4.2 Central Pharma Business Overview
  22. 8.4.3 Central Pharma Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Central Pharma Cell and Gene Therapy (CGT) Logistic Product Portfolio
  24. 8.4.5 Central Pharma Recent Developments
  25. 8.5 POLAR EXPRES
  26. 8.5.1 POLAR EXPRES Company Information
  27. 8.5.2 POLAR EXPRES Business Overview
  28. 8.5.3 POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 POLAR EXPRES Cell and Gene Therapy (CGT) Logistic Product Portfolio
  30. 8.5.5 POLAR EXPRES Recent Developments
  31. 8.6 Biocair
  32. 8.6.1 Biocair Company Information
  33. 8.6.2 Biocair Business Overview
  34. 8.6.3 Biocair Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biocair Cell and Gene Therapy (CGT) Logistic Product Portfolio
  36. 8.6.5 Biocair Recent Developments
  37. 8.7 time:matters
  38. 8.7.1 time:matters Company Information
  39. 8.7.2 time:matters Business Overview
  40. 8.7.3 time:matters Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 time:matters Cell and Gene Therapy (CGT) Logistic Product Portfolio
  42. 8.7.5 time:matters Recent Developments
  43. 8.8 Mercury Business Services
  44. 8.8.1 Mercury Business Services Company Information
  45. 8.8.2 Mercury Business Services Business Overview
  46. 8.8.3 Mercury Business Services Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mercury Business Services Cell and Gene Therapy (CGT) Logistic Product Portfolio
  48. 8.8.5 Mercury Business Services Recent Developments
  49. 8.9 Cardinal Health
  50. 8.9.1 Cardinal Health Company Information
  51. 8.9.2 Cardinal Health Business Overview
  52. 8.9.3 Cardinal Health Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cardinal Health Cell and Gene Therapy (CGT) Logistic Product Portfolio
  54. 8.9.5 Cardinal Health Recent Developments
  55. 8.10 CRYOPDP
  56. 8.10.1 CRYOPDP Company Information
  57. 8.10.2 CRYOPDP Business Overview
  58. 8.10.3 CRYOPDP Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CRYOPDP Cell and Gene Therapy (CGT) Logistic Product Portfolio
  60. 8.10.5 CRYOPDP Recent Developments
  61. 8.11 Cryoport
  62. 8.11.1 Cryoport Company Information
  63. 8.11.2 Cryoport Business Overview
  64. 8.11.3 Cryoport Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cryoport Cell and Gene Therapy (CGT) Logistic Product Portfolio
  66. 8.11.5 Cryoport Recent Developments
  67. 8.12 NMDP BioTherapies
  68. 8.12.1 NMDP BioTherapies Company Information
  69. 8.12.2 NMDP BioTherapies Business Overview
  70. 8.12.3 NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  71. 8.12.4 NMDP BioTherapies Cell and Gene Therapy (CGT) Logistic Product Portfolio
  72. 8.12.5 NMDP BioTherapies Recent Developments
  73. 8.13 McKesson
  74. 8.13.1 McKesson Company Information
  75. 8.13.2 McKesson Business Overview
  76. 8.13.3 McKesson Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  77. 8.13.4 McKesson Cell and Gene Therapy (CGT) Logistic Product Portfolio
  78. 8.13.5 McKesson Recent Developments
  79. 8.14 Excel Courier
  80. 8.14.1 Excel Courier Company Information
  81. 8.14.2 Excel Courier Business Overview
  82. 8.14.3 Excel Courier Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Excel Courier Cell and Gene Therapy (CGT) Logistic Product Portfolio
  84. 8.14.5 Excel Courier Recent Developments
  85. 8.15 Almac
  86. 8.15.1 Almac Company Information
  87. 8.15.2 Almac Business Overview
  88. 8.15.3 Almac Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Almac Cell and Gene Therapy (CGT) Logistic Product Portfolio
  90. 8.15.5 Almac Recent Developments
  91. 8.16 BEAM Logistics
  92. 8.16.1 BEAM Logistics Company Information
  93. 8.16.2 BEAM Logistics Business Overview
  94. 8.16.3 BEAM Logistics Cell and Gene Therapy (CGT) Logistic Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BEAM Logistics Cell and Gene Therapy (CGT) Logistic Product Portfolio
  96. 8.16.5 BEAM Logistics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst